Navigation Links
Genaera Liquidating Trust To Sell Remaining Proprietary Assets
Date:1/11/2010

SOUTHAMPTON, Pa., Jan. 11 /PRNewswire/ -- Argyce LLC, the trustee of the Genaera Liquidating Trust (the "Trust"), http://www.genaera.com, will divest the remaining drug development program assets of Genaera Corporation on an "as-is" basis. The Trust is soliciting bids to be received no later than February 12, 2010 for the assets, which may be purchased separately or in combination. Any person interested in purchasing the assets or learning more about the bidding process should contact the trustee's CEO, John Skolas.

The assets to be sold include the following:

  • IL-9 Antibody Licensor's Interest: AstraZeneca, through its subsidiary, MedImmune, Inc., is actively developing MEDI-528, a fully humanized monoclonal antibody to interleukin-9 ("IL-9"), as therapy for moderate to severe persistent asthma (collectively "the IL-9 program") and has announced its intention to proceed to a phase 2b trial. The Trust holds the licensor's interest formerly held by Genaera Corporation in the IL-9 antibody program, which includes rights to development and sales milestones and royalties on approved product sales; and
  • Pexiganan Acetate: Pexiganan is a novel, small peptide anti-infective, active against multi-drug resistant bacteria (MRSA, MDRAB), developed in a topical cream form. Pexiganan is the subject of an open IND and a pending New Drug Application ("NDA") for diabetic foot infection. In clinical trials conducted by Genaera, over 1,000 human subjects were exposed to pexiganan without safety concerns, including 418 patients who received pexiganan in two phase 3 clinical trials submitted in a NDA to the U.S. Food and Drug Administration in 1998.

Interested parties can obtain a copy of a non-confidential information package for each product along with a Confidential Disclosure Agreement ("CDA") by contacting John Skolas (trustee@genaera.com, phone 267-988-4079), Genaera Liquidating Trust, 610 Second Street Pike, Southampton, PA 18966. Following execution of the CDA, a confidential information package will be provided for each product.

The Genaera Liquidating Trust is managed by Argyce LLC, a boutique consulting and interim management firm focused on companies in transition - typically in early or late stages of a small company life cycle. Examples of such transitions include companies undergoing major management changes, start ups moving from incubator to operating stage, managed liquidations, liquidating trust services for life sciences companies and crises requiring creativity and stability.

ARGYCE serves small public companies and private equity/venture backed private companies. http://www.argyce.com .

SOURCE Genaera Liquidating Trust

RELATED LINKS
http://www.genaera.com

'/>"/>

SOURCE Genaera Liquidating Trust
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genaera Receives Non-Compliance Notice from Nasdaq
2. Genaera to Present at BIO-Europe 2008
3. Genaera Corporation Announces Second Quarter Financial Results
4. Genaera Corporation Elects Paul K. Wotton to Board of Directors
5. Genaera Corporation to Present at BIO Business Forum
6. Genaera Corporation Announces First Quarter Financial Results
7. Genaera Corporation Announces 2007 Financial Results
8. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
9. Genaera Corporation Announces Third Quarter Financial Results
10. Genaera to Present at Biotech 2007 and BIO InvestorForum
11. Genaera Elects New Board Member and Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling ... early-stage tech companies. “Grit” author Angela Duckworth and her team at Character Lab ... is Cooley, an international law firm with decades of experience supporting high-growth companies ...
(Date:9/19/2017)... ValGenesis Inc., the global leader in Enterprise ... the strategic partnership with VTI Life Sciences (VTI). This ... using the latest technology available in the ValGenesis VLMS ... efficient and cost-effective validation services using ValGenesis VLMS. VTI ... VLMS system. The ...
(Date:9/19/2017)... ... September 19, 2017 , ... Band-LOK, LLC, an orthopedic medical ... two new patents have been allowed by the USPTO on the proprietary Tether ... continue to explore additional clinically-relevant designs for both the implants and the instrumentation. ...
(Date:9/18/2017)... (PRWEB) , ... September 18, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... ServiceMax Maximize 2017 conference. , What: Digital Transformation in Medical Device – The ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):